CNN (5/16) reports that the FDA “has given marketing clearance to a blood test to help diagnose Alzheimer’s disease, making the test the first to get signoff to aid in the early detection of the disease in the” US. This “test, called the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, is for adults 55 and older who are showing signs and symptoms of Alzheimer’s disease, the FDA announced.” Also covering the story are the Washington Post (5/16, Gilbert, Roubein), The Hill (5/16, Choi), the AP (5/16, Perrone), and Reuters (5/16, Santhosh). (SOURCE: APA Headlines)